Combination DMARDs more cost-effective with comparable lifetime results than anti-TNF therapy in treating rheumatoid arthritis
Monday, October 28, 2013 - 08:20
in Health & Medicine
Starting with a combination of three traditional disease-modifying antirheumatic drugs (called DMARDs) for treating early rheumatoid arthritis is more cost-effective long term, with comparable benefits, than using either an immediate or step-up approach with anti-tumor necrosis factor (called Anti-TNFs) drugs and methotrexate, according to new research.